Mexiletine in a Newborn with Type 3 Long QT Syndrome: When Access is Difficult

Arq Bras Cardiol. 2022 May;118(5):989-991. doi: 10.36660/abc.20210533.
[Article in English, Portuguese]
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-Arrhythmia Agents / adverse effects
  • Electrocardiography
  • Humans
  • Infant, Newborn
  • Long QT Syndrome* / diagnosis
  • Long QT Syndrome* / drug therapy
  • Mexiletine* / therapeutic use

Substances

  • Anti-Arrhythmia Agents
  • Mexiletine